Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Targeting Melasma: Innovations in Pigment Deposition and Photoaging in Cosmetic Dermatology

Liao T., Luo R., Deng Y., Yang H., Du Y.

Clinical Trial on Skin Aging, published in J Cosmet Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Cosmet Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41508749
PMCID
PMC12783984
DOI
10.1111/jocd.70665
Citations
1

Abstract (original English)

Background Melasma is a chronic, relapsing hyperpigmentation disorder driven by complex interactions among genetic predisposition, hormonal fluctuations, UV exposure, oxidative stress, inflammation, and photoaging. Its psychosocial impact is substantial, especially among women with darker skin types, and treatment remains challenging due to its multifactorial pathogenesis and high recurrence rates. Aims This review aims to synthesize current knowledge on melasma pathophysiology, highlight recent innovations in topical and procedural therapies, identify limitations of existing treatments, and outline future directions toward personalized and regenerative approaches. Patients/methods A narrative literature review was performed, summarizing findings from epidemiologic studies, molecular investigations, and clinical trials. Key topics included pigment biology, hormonal and environmental triggers, oxidative stress pathways, emerging depigmenting agents, laser and microneedling technologies, combination therapies, and advances in precision medicine. Results Melasma arises from dysregulated melanogenesis involving hyperactive melanocytes, hormonal stimulation, UV-induced oxidative stress, dermal inflammation, fibroblast senescence, and pigmentary incontinence. Innovations include non-hydroquinone brighteners (e.g., thiamidol, melasyl), antioxidants, tranexamic acid, and improved topic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansMelanosisDermatologic AgentsSkin PigmentationCombined Modality TherapyCosmetic TechniquesAdministration, CutaneousOxidative StressSkin AgingSkin Lightening Preparations

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research